Back to Newsroom
Back to Newsroom

LAWSUITS FILED AGAINST ZY, ITRM and ANVS - Jakubowitz Law Pursues Shareholders Claims

Monday, 30 August 2021 05:25 PM

Jakubowitz Law

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / August 30, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Zymergen Inc. (NASDAQ:ZY)

CONTACT JAKUBOWITZ ABOUT ZY:
https://claimyourloss.com/securities/zymergen-inc-loss-submission-form/?id=19139&from=1

This lawsuit is on behalf of investors who purchased ZY common stock pursuant and/or traceable to the documents issued in connection with the Company's April 2021 initial public offering.

Lead Plaintiff Deadline: October 4, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) during the qualification process for the Company's optical film product, Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers' processes; (2) though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) as a result, the Company overestimated demand for its products; (4) as a result of the foregoing, the Company's product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Iterum Therapeutics Plc (NASDAQ:ITRM)

CONTACT JAKUBOWITZ ABOUT ITRM:
https://claimyourloss.com/securities/iterum-therapeutics-plc-loss-submission-form/?id=19139&from=1

Class Period : November 30, 2020 - July 23, 2021

Lead Plaintiff Deadline : October 4, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Annovis Bio, Inc. (NYSE:ANVS)

CONTACT JAKUBOWITZ ABOUT ANVS:
https://claimyourloss.com/securities/annovis-bio-inc-loss-submission-form/?id=19139&from=1

Class Period: May 21, 2021 - July 28, 2021

Lead Plaintiff Deadline: October 18, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Annovis's ANVS401 (Posiphen), an orally administrated drug which purportedly inhibited the synthesis of neurotoxic proteins that are the main cause of neurodegeneration, did not show statistically significant results across two patient populations as to factors such as orientation, judgment, and problem solving; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Jakubowitz Law, Monday, August 30, 2021, Press release picture

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: